A Phase III Multicentre, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
This randomized Phase III, multicentre, open-label study is designed to evaluate the safety
and efficacy of MPDL3280A in combination with carboplatin + Nab-paclitaxel compared with
treatment with carboplatin + Nab-paclitaxel in chemotherapy-naive patients with Stage IV
non-squamous non-small cell lung cancer (NSCLC).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society